Ginkgo Bioworks (DNA) Q1 Revenues Beat; Guides Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Ginkgo Bioworks Reports First Quarter 2022 Financial Results
May 16, 2022 4:01 PM EDT$168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021
11 new Cell Programs added in Q1 2022, representing 175% growth over Q1 2021
Increasing full year guidance for Total revenue from $325Â $340 million to $375 $390 million, reiterating Foundry revenue guidance and increasing Biosecurity revenue guidance
Recently announced plans to expand platform capabilities in agricultural biologicals through a series of M&A transactions and flagship collaboration with Bayer
$1.5 billion cash balance provides meaningful multi-year runway as we drive towards... More
